Mast Cells as Drivers of Disease and Therapeutic Targets

被引：98

作者：

Siebenhaar, Frank ^{[1
]}

Redegeld, Frank A. ^{[2
]}

Bischoff, Stephan C. ^{[3
]}

Gibbs, Bernhard F. ^{[4
,5
]}

Maurer, Marcus ^{[1
]}

机构：

[1] Charite, Dept Dermatol & Allergy, Berlin, Germany

[2] Univ Utrecht, Div Pharmacol, Dept Pharmaceut Sci, Fac Sci, Utrecht, Netherlands

[3] Univ Hohenheim, Dept Nutr Med & Immunol, Stuttgart, Germany

[4] Univ Kent, Medway Sch Pharm, Canterbury, Kent, England

[5] Carl von Ossietzky Univ Oldenburg, Dept Dermatol & Allergol, Oldenburg, Germany

来源：

TRENDS IN IMMUNOLOGY | 2018年 / 39卷 / 02期

关键词：

RECEPTOR ANTAGONISTS; SYSTEMIC MASTOCYTOSIS; SKIN INFLAMMATION; CATHEPSIN-G; ALLERGEN; DEGRANULATION; INHIBITION; OMALIZUMAB; MEDIATORS; EFFICACY;

D O I：

10.1016/j.it.2017.10.005

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Mast cells (MCs) contribute to the pathogenesis of a multitude of diseases that include MC-driven disorders such as urticaria, type I allergies, and mastocytosis as well as autoimmune and other inflammatory disorders and malignant tumors. Here, we review and discuss the results of studies that identified and characterized how MCs contribute to disease and, importantly, what strategies may be used to target MCs and MC effects therapeutically. Specifically, we discuss the most common approaches for investigating the role and relevance of MCs in various diseases. We also review current therapeutic approaches aimed at modulating MC numbers, inhibiting MCs and/or preventing MC activation, modulating MC signal transduction and protection from the effects of MC mediators.

引用

页码：151 / 162

页数：12

共 50 条

[31] New oncogenes drivers in lung cancer—new therapeutic targets
Pascale Tomasini
Frederic Fina
Laurent Greillier
Fabrice Barlesi
Current Pulmonology Reports, 2016, 5 (1) : 49 - 56
[32] Polo-like Kinase-1 and Aurora Kinase A As Novel Therapeutic Targets in Neoplastic Mast Cells
Mancini, Manuela
Monaldi, Cecilia
De Santis, Sara
Papayannidis, Cristina
Rondoni, Michela
Abbenante, Maria Chiara
Bavaro, Luana
Martelli, Margherita
Zanotti, Roberta
Pagano, Livio
Cavo, Michele
Valent, Peter
Martinelli, Giovanni
Soverini, Simona
BLOOD, 2017, 130
[33] Mast cell chymase-1 and tryptases: therapeutic targets for COPD?
Liu, Gang
Tiotiu, Angelica
Hansbro, Philip M.
EXPERT OPINION ON THERAPEUTIC TARGETS, 2025, 29 (1-2) : 9 - 12
[34] Molecular targets on mast cells and basophils for novel therapies
Harvima, Ilkka T.
Levi-Schaffer, Francesca
Draber, Petr
Friedman, Sheli
Polakovicova, Iva
Gibbs, Bernhard F.
Blank, Ulrich
Nilsson, Gunnar
Maurer, Marcus
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2014, 134 (03) : 530 - 544
[35] Mast cells as targets for glucocorticoids in the treatment of allergic disorders
Kassel, O
Cato, ACB
RECENT ADVANCES IN GLUCOCORTICOID RECEPTOR ACTION, 2002, 40 : 153 - 176
[36] Mast cells: new targets for multiple sclerosis therapy?
Zappulla, JP
Arock, M
Mars, LT
Liblau, RS
JOURNAL OF NEUROIMMUNOLOGY, 2002, 131 (1-2) : 5 - 20
[37] Mast cells in rheumatic disease
Suurmond, Jolien
van der Velden, Daniel
Kuiper, Johan
Bot, Ilze
Toes, Rene E. M.
EUROPEAN JOURNAL OF PHARMACOLOGY, 2016, 778 : 116 - 124
[38] Mast cells in autoimmune disease
Fehervari, Zoltan
NATURE IMMUNOLOGY, 2018, 19 (04) : 316 - 316
[39] Endothelium, PMNs and mast cells are targets for the antiinflammatory properties of NO
Kubes, P
Gaboury, JP
GASTROENTEROLOGY, 1996, 110 (04) : A339 - A339
[40] Mast cells as a therapeutic target in myeloproliferative neoplasms
Toledo, Marcelo A. S.
Chatain, Nicolas
Zenke, Martin
Koschmieder, Steffen
TRENDS IN MOLECULAR MEDICINE, 2022, 28 (11) : 902 - 905

← 1 2 3 4 5 →